Cargando…

Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up

The prevalence of prostate cancer (PCa) is increasing. As the prognosis of PCa continues to improve, the increasing follow-up requirements after radical prostatectomy or radiotherapy puts significant pressure on health care systems. Follow-up is typically conducted by treating urologists, specialize...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bergroth, Robin, Matikainen, Mika, Rannikko, Antti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Brief Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317875/ https://www.ncbi.nlm.nih.gov/pubmed/34337524 http://dx.doi.org/10.1016/j.euros.2021.04.004

Ejemplares similares

Using a Recurrent Neural Network To Inform the Use of Prostate-specific Antigen (PSA) and PSA Density for Dynamic Monitoring of the Risk of Prostate Cancer Progression on Active Surveillance
por: Sushentsev, Nikita, et al.
Publicado: (2023)

Aggressive Prostate Cancer at Presentation Following Solid Organ Transplantation
por: Singh, Zorawar, et al.
Publicado: (2022)

Telehealth use and perceptions among prostate cancer survivors
por: Chen, Luke W., et al.
Publicado: (2023)

Salvage Radiotherapy Following Partial Gland Ablation for Prostate Cancer: Functional and Oncological Outcomes
por: Qaoud, Yazan, et al.
Publicado: (2020)

Does Protocol Make a Difference? Comparison of Two Prostate Cancer Active Surveillance Cohorts: A Non–protocol-based Follow-up and a Protocol-based Contemporary Follow-up
por: Kalalahti, Inari, et al.
Publicado: (2021)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

How to follow the new EU Council recommendation and improve prostate cancer early detection: the Prostaforum 2022 declaration
por: Májek, Ondřej, et al.
Publicado: (2023)

Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms
por: Tzeng, Michael, et al.
Publicado: (2021)

Synthetic CRISPR/dCas9-KRAB system driven by specific PSA promoter suppresses malignant biological behavior of prostate cancer cells through negative feedback inhibition of PSA expression
por: Yang, Yi, et al.
Publicado: (2023)

Geographic-Level Association of Contemporary Changes in Localized and Metastatic Prostate Cancer Incidence in the Era of Decreasing PSA Screening
por: Yang, Daniel X., et al.
Publicado: (2020)

Can Exercise Adaptations Be Maintained in Men with Prostate Cancer Following Supervised Programmes? Implications to the COVID-19 Landscape of Urology and Clinical Exercise
por: Lopez, Pedro, et al.
Publicado: (2020)

Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy
por: Sandeman, Kevin, et al.
Publicado: (2020)

Early Experience with MRI-ultrasound Fusion-guided Prostate Biopsy in Japanese Men with Elevated PSA Levels
por: Tamada, Tsutomu, et al.
Publicado: (2019)

What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021
por: Turco, Fabio, et al.
Publicado: (2022)

Novel Tools for Prostate Cancer Prognosis, Diagnosis, and Follow-Up
por: Dimakakos, Andreas, et al.
Publicado: (2014)

Implementation of 4Kscore as a Secondary Test Before Prostate Biopsy: Impact on US Population Trends for Prostate Cancer
por: Scuderi, Simone, et al.
Publicado: (2023)

Prostate Cancer Risk by BRCA2 Genomic Regions
por: Nyberg, Tommy, et al.
Publicado: (2020)

Dynamic Contrast-Enhanced Imaging as a Prognostic Tool in Early Diagnosis of Prostate Cancer: Correlation with PSA and Clinical Stage
por: Wu, Xingchen, et al.
Publicado: (2018)

The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer
por: Shaw, Greg L., et al.
Publicado: (2016)

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
por: Strittmatter, F, et al.
Publicado: (2011)

Addition of a Genetic Risk Score for Identification of Men with a Low Prostate-specific Antigen Level in Midlife at Risk of Developing Lethal Prostate Cancer
por: Ma, Chaoran, et al.
Publicado: (2023)

Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [(177)Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer
por: Stangl-Kremser, Judith, et al.
Publicado: (2021)

Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand
por: Obertová, Zuzana, et al.
Publicado: (2014)

Micro-ultrasound Versus Magnetic Resonance Imaging in Prostate Cancer Active Surveillance
por: Albers, Patrick, et al.
Publicado: (2022)

Clinical and Genomic Factors Associated with Greater Tumor Mutational Burden in Prostate Cancer
por: Hougen, Helen Y., et al.
Publicado: (2023)

Telehealth use in antenatal care? Not without women's voices
por: Galle, Anna, et al.
Publicado: (2021)

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
por: Fallara, Giuseppe, et al.
Publicado: (2023)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer
por: Burchardt, Wojciech, et al.
Publicado: (2018)

Implications of the European Association of Urology Recommended Risk Assessment Algorithm for Early Prostate Cancer Detection
por: Israël, Bas, et al.
Publicado: (2022)

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
por: Azab, Sherif, et al.
Publicado: (2012)

Employing telehealth within HIV care: advantages, challenges, and recommendations
por: Grove, Melissa, et al.
Publicado: (2021)

Clinical Use of [-2]proPSA (p2PSA) and Its Derivatives (%p2PSA and Prostate Health Index) for the Detection of Prostate Cancer: A Review of the Literature
por: Abrate, Alberto, et al.
Publicado: (2014)

Leveraging Social Media as a Thermometer to Gauge Patient and Caregiver Concerns: COVID-19 and Prostate Cancer
por: Loeb, Stacy, et al.
Publicado: (2021)

The Relationship between Prostate Biopsy Results and PSA and Free PSA Ratio Changes in Elevated Serum PSA Patients with and without Antibiotherapy
por: Duran, Mesut Berkan, et al.
Publicado: (2020)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
por: Murray, Nigel P., et al.
Publicado: (2014)

Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer
por: Cho, Hyungseok, et al.
Publicado: (2022)

In-depth Analysis of the 2019 Advanced Prostate Cancer Consensus Conference: The Importance of Representation of Medical Specialty and Geographic Regions
por: Pratsinis, Manolis, et al.
Publicado: (2021)

Oligometastasis in Prostate Cancer: Can We Learn from Those “Excluded” from a Phase 2 Trial?
por: Glicksman, Rachel M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_oo41ass2mdem15jk11g95eo8je